<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463110</url>
  </required_header>
  <id_info>
    <org_study_id>P110155</org_study_id>
    <nct_id>NCT02463110</nct_id>
  </id_info>
  <brief_title>Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin</brief_title>
  <acronym>ANDROS</acronym>
  <official_title>Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin: The ANDROS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Action Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose:&#xD;
&#xD;
      To evaluate the evolution in time of the antiaggregant platelet effect of sertraline (SSRI)&#xD;
      compared to placebo in depressive patients with ACS (Acute Coronary Syndrome) and treated as&#xD;
      recommended by a double antiplatelet therapy, aspirin and clopidogrel.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The benefits of SSRIs observed in depressive patients with ACS are related to an antiplatelet&#xD;
      effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational:&#xD;
&#xD;
      40% of patients hospitalized for acute coronary syndrome (ACS) present depressive symptoms.&#xD;
      The increase in cardiovascular morbidity and mortality at 6 months (hazard ratio = 3.5) could&#xD;
      partly be explained by an alteration of the platelet parameters in patients with depression.&#xD;
&#xD;
      Sertraline is a potent inhibitor of the selective serotonin reuptake (SSRI). At the platelet&#xD;
      level, it decreases the secretion induced by collagen and causes the inhibition of serotonin&#xD;
      reuptake and platelet activation, wider than the simple anti-serotonergic effect. Its&#xD;
      efficacy on depression of patients with ACS has been demonstrated (-20% of ischemic events at&#xD;
      24 weeks vs placebo), partly independent of the correction of depressive symptoms, and with a&#xD;
      wide safety action. Antiplatelet, anti-inflammatory and endothelial function effects of&#xD;
      sertraline are demonstrated in healthy volunteers, in stable patients and in patients with&#xD;
      heart failure, but have never been explored in ACS .&#xD;
&#xD;
      Multicenter, randomized, double-blind, controlled trial comparing SSRI and placebo in&#xD;
      depressive patients with ACS.&#xD;
&#xD;
      A control (non depressive) ACS group will also do the clinical and laboratory follow-up at&#xD;
      the same time (without drug administration), to constitute a reference for platelet&#xD;
      parameters and to allow a comparison with the depressive ACS group treated with placebo.&#xD;
&#xD;
      Randomization and initiation of the treatment at the end of the hospitalization for ACS&#xD;
      (possibly after reperfusion and stabilization of cardiac medication)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator's decision&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time dependent pattern of changes in platelet reactivity under sertraline compared to placebo within a time Frame of 6 months of treatment</measure>
    <time_frame>0 day, 1 day, 6 weeks, 24 weeks, 28 weeks</time_frame>
    <description>To evaluate the time variation of the level of platelet reactivity (ADP induced residual aggregation) under sertraline compared to placebo within a time Frame of 6 months of treatment.&#xD;
Time Frame:&#xD;
T0 = before starting treatment with sertraline T1 = at discharge from the hospital = J1 after introduction of treatment with sertraline T2 = 6 weeks of treatment with sertraline T3 = 24 weeks of treatment with sertraline = end of treatment with sertraline T4 = 4 weeks after the end of treatment with sertraline (biological and psychiatric rebound)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time dependent pattern of changes in platelet activation</measure>
    <time_frame>0 day, 1 day, 6 weeks, 24 weeks, 28 weeks</time_frame>
    <description>Maximal platelet aggregation (ADP, Arachidonic Acid, Collagen), markers of platelet activation (betaTG, CD40s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time dependent pattern of changes in inflammation markers</measure>
    <time_frame>0 day, 1 day, 6 weeks, 24 weeks, 28 weeks</time_frame>
    <description>Dosage of inflammation markers (IL-6, CRP, Fg, myeloperoxydase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time dependent changes in Depression</measure>
    <time_frame>0 day, 1 day, 6 weeks, 24 weeks, 28 weeks</time_frame>
    <description>Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time dependent changes in Tobacco addiction</measure>
    <time_frame>0 day, 1 day, 6 weeks, 24 weeks, 28 weeks</time_frame>
    <description>Fargenström test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time dependent changes in Bleeding risk</measure>
    <time_frame>0 day, 1 day, 6 weeks, 24 weeks, 28 weeks</time_frame>
    <description>Dosage of hemoglobin, hematocrit and follow-up of hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Depression</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1: Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACS, depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ACS, depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ACS, no depression, no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.</description>
    <arm_group_label>1: Sertraline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <arm_group_label>3: Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2: Placebo</arm_group_label>
    <other_name>Placebo one capsule, which can be increased up to 4 capsules per day (maximum dose) for 6 months.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient Aged 18 years and older&#xD;
&#xD;
          -  Patient Depressive without antidepressant therapy for three months (valid only for the&#xD;
             sertraline and placebo groups)&#xD;
&#xD;
          -  Patient With ACS with elevated cardiac enzymes (above the 99th percentile of the upper&#xD;
             limit of normal of the laboratory)&#xD;
&#xD;
          -  Patient That assessed depressive symptoms : Test Beck (13 items)&#xD;
&#xD;
          -  Patient Affiliated to a social security scheme (beneficiary or assignee)&#xD;
&#xD;
          -  Patient Having signed a free and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular&#xD;
&#xD;
               -  History of serious bleeding (recent hemoglobin fall 5g / dl ( &lt;3 months ),&#xD;
                  intracranial hemorrhage or hemorrhagic tamponade)&#xD;
&#xD;
               -  Uncontrolled hypertension (SBP &gt; 180 mmHg or DBP &gt; 100 mmHg)&#xD;
&#xD;
               -  Stroke &lt;3 months&#xD;
&#xD;
               -  Treatment with ticagrelor or prasugrel for the duration of the study.&#xD;
&#xD;
          -  Psychiatric&#xD;
&#xD;
               -  Psychosis, bipolar illness&#xD;
&#xD;
               -  Dementia (Mini- Mental State Examination score &lt; 23)&#xD;
&#xD;
               -  Uncontrolled epilepsy&#xD;
&#xD;
               -  Severe depression (score &gt; 15) with suicidal risk identified by a psychiatrist&#xD;
                  (urgent treatment for depression needed)&#xD;
&#xD;
               -  Patient experienced depression and treated in the last three months or currently&#xD;
                  receiving treatment&#xD;
&#xD;
               -  Treatment with selective and non-selective monoamine oxidase inhibitors of the&#xD;
                  group A within 14 days prior to the introduction of sertraline&#xD;
&#xD;
          -  Clinical and Biological&#xD;
&#xD;
               -  Prothrombin time &gt; 1.5 second&#xD;
&#xD;
               -  Platelet rate &lt; 100 000 / mm3&#xD;
&#xD;
               -  Hematocrit rate &lt; 25%&#xD;
&#xD;
               -  Serum creatinine &gt; 4.0 mg / dl&#xD;
&#xD;
               -  Severe hepatic impairment (Child Pugh stage C)&#xD;
&#xD;
          -  Contraindications to sertraline (placebo / sertraline group)&#xD;
&#xD;
               -  Hypersensitivity to the active substance or to any of the excipients (anhydrous&#xD;
                  lactose, pregelatinized corn starch, sodium laurilsulfate , magnesium stearate)&#xD;
&#xD;
               -  Treatment with pimozide&#xD;
&#xD;
               -  Genetic galactose intolerance, malabsorption of glucose and galactose, lactase&#xD;
                  deficiency&#xD;
&#xD;
          -  Regulatory&#xD;
&#xD;
               -  Women without effective contraception or pregnant or lactating or desiring&#xD;
                  pregnancy or within 6 months after randomization&#xD;
&#xD;
               -  Participation in biomedical research on other drugs during the period of&#xD;
                  participation&#xD;
&#xD;
               -  Patients unable to follow the treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanne SILVAIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACTION Group - Pitié-Salpêtrière University Hospital (APHP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Depression</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

